We've reached the afternoon of Day 4 of #RCPsychIC - and right now we're anticipating our next keynote, which is titled Rapid-Acting Antidepressants: New treatments, new hope, and new insights into the brain.
Our speaker is one of the most influential psychiatrists in biological psychiatry - Dr John Krystal from @Yale - who says the STAR*D study showed too few saw remission from depression from antidepressants and in other analyses ADs proved less effective than we thought #RCPsychIC
@Yale Why ketamine? We recognised we needed to shift from serotonin targeting the mid brain towards medication to affect the cortex and limbic system, and this led us to ketamine says Dr Krystal #RCPsychIC
@Yale Study showed use of esketamine protects the patient against relapse says Dr Krystal #RCPsychIC 
@Yale It's also been shown that ketamine is a rapidly acting and effective antidepressant when it comes to reducing suicidal ideation says Dr Krystal #RCPsychIC
@Yale It is important to establish the narrow dose range at which ketamine is effective says Dr Krystal - the diagram below illustrates this #RCPsychIC
@Yale Different genes are turned on by ketamine's administration and they have different functions says Dr Krystal. Ketamine blocks activation of NMDA receptors reducing inhibition and glutamate release is increased #RCPsychIC
@Yale Studies suggest ketamine offers new clinical opportunities with promise of rapid results for treatment resistant symptoms. In addition, what we understand abt how ketamine is working sheds new light on brain mechanisms in depression + treatment says Dr Krystal. #RCPsychIC
• • •
Missing some Tweet in this thread? You can try to
force a refresh
